安成生技 6610.TW Overview
6610
安成生技
0.26%
(0.00)
6610 AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
6610 Current Performance
0.26%
安成生技
0.22%
Avg of Sector
0.91%
TAIEX
6610 Key Information
6610 Revenue by Segments
Browsing restrictions can be lifted for a fee.
6610 Net Income
Browsing restrictions can be lifted for a fee.
6610 Cash Flow
Browsing restrictions can be lifted for a fee.
6610 Profit Margin
Browsing restrictions can be lifted for a fee.
6610 PE Ratio River
Browsing restrictions can be lifted for a fee.
6610 Profile
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseases. It has a drug development agreement with Hong Kong Winhealth Pharma Group Co., Limited. in Mainland China, Hong Kong, and Macao markets. TWi Biotechnology, Inc. was founded in 2010 and is based in Taipei, Taiwan.
6610 FAQ
When is 6610's latest earnings report released?
The most recent financial report for 安成生技 (6610) covers the period of 2024Q4 and was published on 2024/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6610's short-term business performance and financial health. For the latest updates on 6610's earnings releases, visit this page regularly.
How much cash does 6610 have?
At the end of the period, 安成生技 (6610) held Total Cash and Cash Equivalents of 126.8M, accounting for 0.52 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is 6610's EPS continuing to grow?
According to the past four quarterly reports, 安成生技 (6610)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.78. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.